Antiangiogenic therapy in the treatment of soft tissue sarcomas
Soft tissue sarcomas are tumors with high level of vascularization, so angiogenesis plays important role in tumor development and metastasis. Inhibitors of angiogenesis: bevacisumab, sunitinib, sorafenib were studied in clinical trials for the treatment of soft tissue sarcomas. During phase II clinical study the lack of efficacy of monotherapy with bevacisumab, sunitinib, sorafenib was proved. Phase III study PALETTE showed efficacy and safety of pazopanib usage in patients with advanced soft tissue sarcomas who were pretreated with chemotherapy (noGIST, noadipocytic sarcomas). It seems promising to continue the study of efficacy and safety of combination of targeted agents and conventional chemotherapy.